Andres Gomez: Venetoclax can be effectively reduced to 100 mg when combined with azoles in a first-line, phase 2 trial done under limited resources.

Andres Gomez, an Associate Professor at Universidad Autónoma de Nuevo León, Mexico, recently tweeted:

“Venetoclax is an expensive life-saving drug in AML. We have proven it can be effectively reduced to 100 mg when combined with azoles in a first-line, phase 2 trial done under limited resources.

Out now in Leuk Res, access here:”

Source: Andres Gomez/Twitter